Abiopharma

🔍 Began Marc A (Executive)

Company: Axogen, Inc. (AXGN)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 67,500 shares of Common Stock at $8.16 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 117,635.00 | transaction_form_type: 4
• Sold 67,500 shares of Common Stock at $47.345 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,135.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 67,500 shares of Employee Stock Option (right to buy) at $8.16 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2033-03-01 | equity_swap_involved: 0 | shares_owned_after: 22,500.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.
• F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F3: All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.